```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:15:01 ON 01 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   31 AUG 2009  HIGHEST RN 1178609-15-8
DICTIONARY FILE UPDATES:  31 AUG 2009  HIGHEST RN 1178609-15-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l10
L1             1 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  US20070167459 /PN
L2               TRANSFER  PLU=ON  L1 1- RN :    1829 TERMS
L3          1829 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L2
L6               STR
 Hy^Hy^G1       N~^G2^Hy        N~^~N        N~^G3~^N        N~^Hy
  1   2   3       @4   5   6       @7  8       @9  10  11      @12 13


 N~^G3^Hy
@14 15  16

VAR G1=4/7/9/12/14
REP G2=(0-3) C
VAR G3=AK/CB
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E6 C  E1 N  AT   1
ECOUNT  IS E4 C  E2 N  AT   2
ECOUNT  IS M3-X6 C  E1 N  AT   6
ECOUNT  IS M1 N  AT  13
ECOUNT  IS M1 N  AT  16

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L7         10275 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC6 AND NCNC3)/ES
L8          1375 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L7 AND L3
L10         1367 SEA FILE=REGISTRY SUB=L8 SSS FUL L6

100.0% PROCESSED    1375 ITERATIONS                          1367 ANSWERS
SEARCH TIME: 00.00.01



=> b zcap
FILE 'ZCAPLUS' ENTERED AT 13:15:07 ON 01 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
```

FILE COVERS 1907 - 1 Sep 2009 VOL 151 ISS 10
FILE LAST UPDATED: 31 Aug 2009 (20090831/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> d bib abs hitrn fhitstr l12 tot

L12 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:383484 ZCAPLUS
DN 144:428460
TI Method for measuring cell migration activity
IN Shibayama, Shiro; Takeda, Kazuhiko; Watanabe, Noriki; Sugiyama, Tetsuya
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2006043586	A1	20060427	2005WO-JP0019187	20051019
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	2004JP-000305003	A	20041020		

AB A method is provided for measuring the cell migration activity corresponding to the function of a specific cell migration inducer in vivo. The method comprises: (1) a process for transferring cells producing a cell migration inducer (e.g., MDC, SDF-1) into an air-pouch produced under a skin of a mammal (e.g., mouse) ; (2) a process for transferring cells to be measured (e.g., T cells, B cells, monocytes, macrophages, granulocytes) into a site other than the air-pouch of the mammal; (3) a process for recovering the cells in the air-pouch; and (4) a process for measuring the number of the cells to be measured in the recovered cells. Also provided are a method for evaluating a cell migration inhibitory compound possessing a specificity or a selectivity in vivo using the above method; and a method for producing the above cell migration inhibitory compound

IT **710981-61-6**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for measuring cell migration activity)

IT **710981-61-6**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for measuring cell migration activity)

RN 710981-61-6 ZCAPLUS
CN Methanone, cyclohexyl[(3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:515487 ZCAPLUS
DN 141:71555
TI Preparation of nitrogen-containing heterocyclic compounds as CXCR4 regulators
IN Habashita, Hiromu; Kokubo, Masaya; Shibayama, Shiro; Tada, Hideaki; Tanihiro, Tatsuya
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 641 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004052862	A1	20040624	2003WO-JP0015718	20031209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2003288994	A1	20040630	2003AU-000288994	20031209
	EP-----1571146	A1	20050907	2003EP-00077853	20031209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US-20070167459	A1	20070719	2005US-00053858	20050610
PRAI	2002JP-000357446	A	20021210		
	2003JP-000162706	A	20030606		
	2003WO-JP0015718	W	20031209		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:71555
GI



AB Compds. such as pyrimidine and quinazoline derivs. represented by the following general formulas (I) and (II), salts thereof, N-oxides thereof, solvates thereof or prodrugs of the same (wherein the ring A represents an optionally substituted nitrogen-containing heterocycle; the ring B represents an optionally substituted homocycle or an optionally substituted heterocycle; Y represents an optionally substituted hydrocarbyl group, an optionally substituted heterocyclic group, an optionally protected amino group, an optionally protected hydroxyl group or an optionally protected mercapto group; and T represents the ring A or an optionally substituted amino group) are prepared These compds. are CXCR4 regulators, in particular CXCR4 antagonists, and useful as preventives and/or remedies for various inflammatory diseases, immune diseases, various allergic diseases, infectious diseases, acquired immunodeficiency syndrome, infection with human immunodeficiency virus, psychiatric disorder, neurol. disease, cerebral diseases, cardiovascular diseases, metabolic diseases, or cancer, and agents for regeneration therapy, in particular transplant therapy. An assay system using SDF-1 which is an endogenous ligand of CXCR4 receptor, instead of HIV, was used in an assay for screening compds. which inhibit the binding of HIV to CXCR4 or CCR4 receptors on CD4-pos. cells. All the compds. prepared showed IC50 of 10 μM for inhibiting the binding of [125I]human SDF-1 to CEM cells, more specifically 0.1 μM for 2-(1-benzylpyrrolidin-3-ylamino)-4-(perhydroazepin-1-yl)pyrimidine. An ampule and tablet formulation containing 2-[[2-(dimethylamino)ethyl]amino]-4-(perhydroazepin-1-yl)pyrimidine were described.

IT **710978-26-0P** **710978-30-6P** **710978-41-9P**
710978-46-4P **710978-49-7P** **710978-55-5P**
710978-59-9P **710978-64-6P** **710978-70-4P**

L12 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

710978-75-9P **710979-06-9P** **710979-13-8P**
710979-20-7P **710979-27-4P** **710979-44-5P**
710979-47-8P **710979-52-5P** **710979-57-0P**
710979-61-6P **710979-68-3P** **710979-72-9P**
710979-75-2P **710979-80-9P** **710979-86-5P**
710979-90-1P **710979-97-8P** **710980-03-3P**
710980-09-9P **710980-15-7P** **710980-23-7P**
710980-40-8P **710980-47-5P** **710980-52-2P**
710980-59-9P **710980-78-2P** **710980-84-0P**
710980-99-7P **710981-09-2P** **710981-15-0P**
710981-21-8P **710981-39-8P** **710981-47-8P**
710981-54-7P **710981-61-6P** **710981-68-3P**
710981-76-3P **710981-83-2P** **710981-90-1P**
710981-97-8P **710982-05-1P** **710982-11-9P**
710982-16-4P **710982-22-2P** **710982-28-8P**
710982-39-1P **710982-50-6P** **710982-55-1P**
710982-60-8P **710982-65-3P** **710982-71-1P**
710982-75-5P **710982-81-3P** **710982-85-7P**
710982-89-1P **710982-93-7P** **710982-99-3P**
710983-04-3P **710983-09-8P** **710983-14-5P**
710983-18-9P **710983-22-5P** **710983-27-0P**
710983-31-6P **710983-35-0P** **710983-40-7P**
710983-46-3P **710983-55-4P** **710983-74-7P**
710983-78-1P **710983-82-7P** **710983-86-1P**
710983-90-7P **710983-97-4P** **710984-39-7P**
710984-43-3P **710984-47-7P** **710984-51-3P**
710984-55-7P **710984-70-6P** **710984-72-8P**
710984-74-0P **710984-77-3P** **710984-80-8P**
710985-25-4P **710985-82-3P** **710985-84-5P**
710985-86-7P **710985-88-9P** **710985-90-3P**
710985-92-5P **710985-94-7P** **710985-96-9P**
710985-98-1P **710986-00-8P** **710986-02-0P**
710986-05-3P **710986-08-6P** **710986-11-1P**
710986-14-4P **710986-17-7P** **710986-20-2P**
710986-23-5P **710986-26-8P** **710986-29-1P**
710986-33-7P **710986-36-0P** **710986-39-3P**
710986-42-8P **710986-45-1P** **710986-49-5P**
710986-53-1P **710986-56-4P** **710986-59-7P**
710986-62-2P **710986-65-5P** **710986-68-8P**
710986-71-3P **710986-74-6P** **710986-77-9P**
710986-81-5P **710986-85-9P** **710986-89-3P**
710986-93-9P **710986-96-2P** **710987-00-1P**
710987-04-5P **710987-08-9P** **710987-12-5P**
710987-15-8P **710987-18-1P** **710987-21-6P**
710987-24-9P **710987-27-2P** **710987-30-7P**
710987-34-1P **710987-37-4P** **710987-40-9P**
710987-43-2P **710987-46-5P** **710987-48-7P**
710987-51-2P **710987-54-5P** **710987-57-8P**
710987-60-3P **710987-63-6P** **710987-66-9P**
710987-69-2P **710987-72-7P** **710987-76-1P**
710987-79-4P **710987-82-9P** **710987-85-2P**
710987-88-5P **710987-90-9P** **710987-94-3P**
710987-97-6P **710988-00-4P** **710988-04-8P**
710988-07-1P **710988-10-6P** **710988-13-9P**
710988-16-2P **710988-19-5P** **710988-22-0P**
710988-25-3P **710988-28-6P** **710988-31-1P**
710988-35-5P **710988-38-8P** **710988-41-3P**
710988-44-6P **710988-47-9P** **710988-50-4P**
710988-53-7P **710988-56-0P** **710988-59-3P**
710988-62-8P **710988-65-1P** **710988-68-4P**
710988-71-9P **710988-74-2P** **710988-77-5P**
710988-80-0P **710988-83-3P** **710988-87-7P**
710988-90-2P **710988-94-6P** **710988-97-9P**
710989-00-7P **710989-03-0P** **710989-06-3P**
710989-09-6P **710989-12-1P** **710989-15-4P**
710989-18-7P **710989-21-2P** **710989-24-5P**
710989-27-8P **710989-31-4P** **710989-34-7P**
710989-37-0P **710989-40-5P** **710989-43-8P**
710989-45-0P **710989-48-3P** **710989-50-7P**
710989-53-0P **710989-56-3P** **710989-59-6P**
710989-62-1P **710989-65-4P** **710989-68-7P**
710989-71-2P **710989-74-5P** **710989-77-8P**
710989-80-3P **710989-85-8P** **710989-88-1P**
710989-90-5P **710989-93-8P** **710989-96-1P**

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

710989-99-4P 710990-01-5P 710990-03-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710990-06-0P 710990-08-2P 710990-10-6P
710990-13-9P 710990-16-2P 710990-19-5P
710990-22-0P 710990-25-3P 710990-28-6P
710990-31-1P 710990-34-4P 710990-37-7P
710990-40-2P 710990-43-5P 710990-45-7P
710990-48-0P 710990-52-6P 710990-54-8P
710990-56-0P 710990-59-3P 710990-62-8P
710990-65-1P 710990-68-4P 710990-71-9P
710990-74-2P 710990-77-5P 710990-80-0P
710990-82-2P 710990-83-3P 710990-84-4P
710990-86-6P 710990-88-8P 710990-90-2P
710990-92-4P 710990-94-6P 710990-96-8P
710990-98-0P 710991-00-7P 710991-02-9P
710991-03-0P 710991-05-2P 710991-07-4P
710991-09-6P 710991-11-0P 710991-13-2P
710991-15-4P 710991-18-7P 710991-20-1P
710991-23-4P 710991-25-6P 710991-27-8P
710991-29-0P 710991-31-4P 710991-33-6P
710991-35-8P 710991-37-0P 710991-39-2P
710991-41-6P 710991-44-9P 710991-46-1P
710991-48-3P 710991-50-7P 710991-52-9P
710991-54-1P 710991-56-3P 710991-59-6P
710991-62-1P 710991-64-3P 710991-66-5P
710991-68-7P 710991-70-1P 710991-72-3P
710991-74-5P 710991-76-7P 710991-78-9P
710991-81-4P 710991-84-7P 710991-87-0P
710991-88-1P 710991-90-5P 710991-92-7P
710991-94-9P 710991-95-0P 710991-97-2P
710991-99-4P 710992-01-1P 710992-02-2P
710992-03-3P 710992-04-4P 710992-05-5P
710992-06-6P 710992-07-7P 710992-08-8P
710992-09-9P 710992-10-2P 710992-11-3P
710992-12-4P 710992-13-5P 710992-14-6P
710992-15-7P 710992-16-8P 710992-17-9P
710992-18-0P 710992-19-1P 710992-20-4P
710992-21-5P 710992-22-6P 710992-23-7P
710992-24-8P 710992-25-9P 710992-26-0P
710992-27-1P 710992-28-2P 710992-29-3P
710992-30-6P 710992-31-7P 710992-32-8P
710992-33-9P 710992-34-0P 710992-35-1P
710992-36-2P 710992-37-3P 710992-38-4P
710992-39-5P 710992-40-8P 710992-41-9P
710992-42-0P 710992-43-1P 710992-44-2P
710992-45-3P 710992-46-4P 710992-47-5P
710992-48-6P 710992-49-7P 710992-50-0P
710992-51-1P 710992-52-2P 710992-53-3P
710992-54-4P 710992-55-5P 710992-56-6P
710992-57-7P 710992-59-9P 710992-60-2P
710992-61-3P 710992-62-4P 710992-63-5P
710992-64-6P 710992-65-7P 710992-66-8P
710992-67-9P 710992-68-0P 710992-69-1P
710992-70-4P 710992-71-5P 710992-72-6P
710992-73-7P 710992-74-8P 710992-75-9P
710992-76-0P 710992-77-1P 710992-78-2P
710992-79-3P 710992-80-6P 710992-81-7P
710992-82-8P 710992-83-9P 710992-85-1P
710992-86-2P 710992-87-3P 710992-88-4P
710992-89-5P 710992-90-8P 710992-91-9P
710992-92-0P 710992-93-1P 710992-94-2P
710992-95-3P 710992-96-4P 710992-97-5P
710992-98-6P 710992-99-7P 710993-00-3P
710993-01-4P 710993-02-5P 710993-03-6P
710993-04-7P 710993-05-8P 710993-06-9P
710993-07-0P 710993-08-1P 710993-09-2P

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

710993-11-6P 710993-12-7P 710993-13-8P
710993-14-9P 710993-15-0P 710993-16-1P
710993-17-2P 710993-18-3P 710993-19-4P
710993-20-7P 710993-21-8P 710993-22-9P
710993-23-0P 710993-24-1P 710993-25-2P
710993-26-3P 710993-27-4P 710993-28-5P
710993-29-6P 710993-30-9P 710993-31-0P
710993-32-1P 710993-33-2P 710993-34-3P
710993-35-4P 710993-36-5P 710993-37-6P
710993-38-7P 710993-39-8P 710993-40-1P
710993-41-2P 710993-42-3P 710993-43-4P
710993-44-5P 710993-45-6P 710993-46-7P
710993-47-8P 710993-49-0P 710993-50-3P
710993-52-5P 710993-54-7P 710993-56-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710993-58-1P 710993-60-5P 710993-62-7P
710993-64-9P 710993-66-1P 710993-68-3P
710993-69-4P 710993-71-8P 710993-73-0P
710993-75-2P 710993-77-4P 710993-78-5P
710993-80-9P 710993-81-0P 710993-83-2P
710993-85-4P 710993-87-6P 710993-89-8P
710993-91-2P 710993-92-3P 710993-94-5P
710993-95-6P 710993-96-7P 710993-97-8P
710993-98-9P 710993-99-0P 710994-00-6P
710994-01-7P 710994-02-8P 710994-03-9P
710994-04-0P 710994-05-1P 710994-06-2P
710994-07-3P 710994-08-4P 710994-09-5P
710994-10-8P 710994-11-9P 710994-12-0P
710994-13-1P 710994-14-2P 710994-15-3P
710994-16-4P 710994-17-5P 710994-18-6P
710994-19-7P 710994-20-0P 710994-21-1P
710994-22-2P 710994-23-3P 710994-24-4P
710994-25-5P 710994-26-6P 710994-28-8P
710994-29-9P 710994-30-2P 710994-31-3P
710994-32-4P 710994-33-5P 710994-35-7P
710994-37-9P 710994-39-1P 710994-41-5P
710994-43-7P 710994-45-9P 710994-47-1P
710994-50-6P 710994-51-7P 710994-52-8P
710994-54-0P 710994-55-1P 710994-56-2P
710994-57-3P 710994-59-5P 710994-60-8P
710994-61-9P 710994-62-0P 710994-63-1P
710994-64-2P 710994-65-3P 710994-66-4P
710994-67-5P 710994-68-6P 710994-69-7P
710994-70-0P 710994-71-1P 710994-72-2P
710994-73-3P 710994-74-4P 710994-75-5P
710994-76-6P 710994-77-7P 710994-78-8P
710994-79-9P 710994-80-2P 710994-84-6P
710994-87-9P 710994-88-0P 710994-89-1P
710994-91-5P 710994-92-6P 710994-93-7P
710994-94-8P 710994-96-0P 710994-97-1P
710994-98-2P 710994-99-3P 710995-00-9P
710995-01-0P 710995-02-1P 710995-03-2P
710995-05-4P 710995-06-5P 710995-07-6P
710995-08-7P 710995-09-8P 710995-10-1P
710995-11-2P 710995-12-3P 710995-13-4P
710995-14-5P 710995-15-6P 710995-16-7P
710995-18-9P 710995-19-0P 710995-20-3P
710995-21-4P 710995-22-5P 710995-24-7P
710995-25-8P 710995-27-0P 710995-28-1P
710995-30-5P 710995-32-7P 710995-33-8P
710995-34-9P 710995-36-1P 710995-37-2P
710995-39-4P 710995-40-7P 710995-41-8P
710995-42-9P 710995-43-0P 710995-45-2P
710995-48-5P 710995-49-6P 710995-51-0P
710995-52-1P 710995-53-2P 710995-54-3P
710995-55-4P 710995-56-5P 710995-58-7P

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

710995-59-8P 710995-60-1P 710995-61-2P
710995-62-3P 710995-64-5P 710995-65-6P
710995-66-7P 710995-67-8P 710995-68-9P
710995-69-0P 710995-70-3P 710995-71-4P
710995-72-5P 710995-73-6P 710995-74-7P
710995-76-9P 710995-78-1P 710995-80-5P
710995-82-7P 710995-83-8P 710995-84-9P
710995-85-0P 710995-86-1P 710995-87-2P
710995-88-3P 710995-89-4P 710995-90-7P
710995-91-8P 710995-92-9P 710995-93-0P
710995-94-1P 710995-95-2P 710995-96-3P
710995-97-4P 710995-98-5P 710995-99-6P
710996-00-2P 710996-01-3P 710996-02-4P
710996-03-5P 710996-04-6P 710996-05-7P
710996-06-8P 710996-07-9P 710996-08-0P
710996-09-1P 710996-10-4P 710996-11-5P
710996-12-6P 710996-13-7P 710996-14-8P
710996-15-9P 710996-16-0P 710996-17-1P
710996-18-2P 710996-19-3P 710996-20-6P
710996-21-7P 710996-22-8P 710996-23-9P
710996-24-0P 710996-25-1P 710996-26-2P
710996-27-3P 710996-28-4P 710996-29-5P
710996-30-8P 710996-31-9P 710996-32-0P
710996-33-1P 710996-34-2P 710996-35-3P
710996-36-4P 710996-37-5P 710996-38-6P
710996-39-7P 710996-40-0P 710996-41-1P
710996-42-2P 710996-43-3P 710996-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710996-45-5P 710996-46-6P 710996-47-7P
710996-48-8P 710996-49-9P 710996-50-2P
710996-51-3P 710996-52-4P 710996-53-5P
710996-54-6P 710996-55-7P 710996-56-8P
710996-57-9P 710996-58-0P 710996-59-1P
710996-60-4P 710996-61-5P 710996-62-6P
710996-63-7P 710996-64-8P 710996-65-9P
710996-66-0P 710996-67-1P 710996-68-2P
710996-69-3P 710996-70-6P 710996-71-7P
710996-72-8P 710996-73-9P 710996-74-0P
710996-75-1P 710996-76-2P 710996-77-3P
710996-78-4P 710996-79-5P 710996-80-8P
710996-81-9P 710996-82-0P 710996-83-1P
710996-84-2P 710996-85-3P 710996-86-4P
710996-87-5P 710996-88-6P 710996-89-7P
710996-90-0P 710996-91-1P 710996-92-2P
710996-93-3P 710996-94-4P 710996-95-5P
710996-96-6P 710996-97-7P 710996-98-8P
710996-99-9P 710997-00-5P 710997-01-6P
710997-02-7P 710997-03-8P 710997-04-9P
710997-05-0P 710997-06-1P 710997-07-2P
710997-08-3P 710997-09-4P 710997-10-7P
710997-11-8P 710997-12-9P 710997-13-0P
710997-14-1P 710997-15-2P 710997-16-3P
710997-17-4P 710997-18-5P 710997-19-6P
710997-20-9P 710997-21-0P 710997-22-1P
710997-23-2P 710997-24-3P 710997-25-4P
710997-26-5P 710997-27-6P 710997-28-7P
710997-29-8P 710997-30-1P 710997-31-2P
710997-32-3P 710997-33-4P 710997-34-5P
710997-35-6P 710997-36-7P 710997-37-8P
710997-38-9P 710997-39-0P 710997-40-3P
710997-41-4P 710997-42-5P 710997-43-6P
710997-44-7P 710997-45-8P 710997-46-9P
710997-47-0P 710997-48-1P 710997-49-2P
710997-50-5P 710997-51-6P 710997-52-7P
710997-53-8P 710997-54-9P 710997-55-0P
710997-56-1P 710997-57-2P 710997-58-3P
710997-59-4P 710997-60-7P 710997-61-8P
710997-62-9P 710997-63-0P 710997-64-1P
710997-65-2P 710997-66-3P 710997-67-4P
710997-68-5P 710997-69-6P 710997-70-9P

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

710997-71-0P 710997-72-1P 710997-73-2P
710997-74-3P 710997-75-4P 710997-76-5P
710997-77-6P 710997-78-7P 710997-79-8P
710997-80-1P 710997-81-2P 710997-82-3P
710997-83-4P 710997-84-5P 710997-85-6P
710997-86-7P 710997-87-8P 710997-88-9P
710997-89-0P 710997-90-3P 710997-91-4P
710997-92-5P 710997-93-6P 710997-94-7P
710997-95-8P 710997-96-9P 710997-97-0P
710997-98-1P 710997-99-2P 710998-00-8P
710998-01-9P 710998-02-0P 710998-03-1P
710998-04-2P 710998-05-3P 710998-06-4P
710998-07-5P 710998-08-6P 710998-09-7P
710998-10-0P 710998-11-1P 710998-12-2P
710998-13-3P 710998-14-4P 710998-15-5P
710998-16-6P 710998-17-7P 710998-18-8P
710998-19-9P 710998-20-2P 710998-21-3P
710998-22-4P 710998-23-5P 710998-24-6P
710998-25-7P 710998-26-8P 710998-27-9P
710998-28-0P 710998-29-1P 710998-30-4P
710998-31-5P 710998-32-6P 710998-33-7P
710998-34-8P 710998-35-9P 710998-36-0P
710998-37-1P 710998-38-2P 710998-39-3P
710998-40-6P 710998-41-7P 710998-42-8P
710998-43-9P 710998-44-0P 710998-45-1P
710998-46-2P 710998-47-3P 710998-48-4P
710998-49-5P 710998-50-8P 710998-51-9P
710998-52-0P 710998-53-1P 710998-54-2P
710998-55-3P 710998-56-4P 710998-57-5P
710998-58-6P 710998-59-7P 710998-60-0P
710998-61-1P 710998-62-2P 710998-63-3P
710998-66-6P 710998-67-7P 710998-68-8P
710999-82-9P 710999-85-2P 710999-88-5P
710999-91-0P 710999-92-1P 711000-15-6P
711000-16-7P 711000-17-8P 711000-18-9P
711001-13-7P 711001-14-8P 711001-19-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 711001-20-6P 711001-27-3P 711001-39-7P
711001-40-0P 711001-41-1P 711001-46-6P
711001-71-7P 711001-73-9P 711001-74-0P
711001-75-1P 711001-76-2P 711001-77-3P
711001-78-4P 711001-79-5P 711001-82-0P
711002-69-6P 711002-70-9P 711002-71-0P
711002-72-1P 711002-75-4P 711002-76-5P
711002-77-6P 711002-78-7P 711002-79-8P
711002-80-1P 711002-81-2P 711002-82-3P
711002-83-4P 711002-84-5P 711002-85-6P
711002-86-7P 711002-87-8P 711002-88-9P
711002-89-0P 711002-90-3P 711002-91-4P
711002-92-5P 711002-93-6P 711002-94-7P
711002-95-8P 711002-96-9P 711002-97-0P
711002-98-1P 711002-99-2P 711003-00-8P
711003-01-9P 711003-02-0P 711003-03-1P
711003-04-2P 711003-05-3P 711003-06-4P
711003-07-5P 711003-08-6P 711003-09-7P
711003-11-1P 711003-12-2P 711003-13-3P
711003-14-4P 711003-15-5P 711003-16-6P
711003-17-7P 711003-18-8P 711003-19-9P
711003-20-2P 711003-21-3P 711003-22-4P
711003-23-5P 711003-24-6P 711003-25-7P
711003-26-8P 711003-27-9P 711003-28-0P
711003-29-1P 711003-30-4P 711003-31-5P
711003-32-6P 711003-33-7P 711003-34-8P
711003-35-9P 711003-36-0P 711003-37-1P
711003-38-2P 711003-39-3P 711003-40-6P
711003-41-7P 711003-42-8P 711003-43-9P
711003-44-0P 711003-45-1P 711003-46-2P
711003-47-3P 711003-48-4P 711003-49-5P
711003-50-8P 711003-51-9P 711003-52-0P
711003-53-1P 711003-54-2P 711003-55-3P

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

711003-56-4P 711003-57-5P 711003-58-6P
711003-59-7P 711003-60-0P 711003-61-1P
711003-62-2P 711003-63-3P 711003-64-4P
711003-65-5P 711003-66-6P 711003-67-7P
711003-68-8P 711003-69-9P 711003-70-2P
711003-71-3P 711003-72-4P 711003-73-5P
711003-74-6P 711003-75-7P 711003-76-8P
711003-77-9P 711003-78-0P 711003-79-1P
711003-80-4P 711003-81-5P 711003-82-6P
711003-83-7P 711003-84-8P 711003-85-9P
711003-86-0P 711003-87-1P 711003-88-2P
711003-89-3P 711003-90-6P 711003-91-7P
711003-92-8P 711003-93-9P 711003-94-0P
711003-95-1P 711003-96-2P 711003-97-3P
711003-98-4P 711003-99-5P 711004-00-1P
711004-01-2P 711004-02-3P 711004-03-4P
711004-04-5P 711004-05-6P 711004-06-7P
711004-07-8P 711004-08-9P 711004-09-0P
711004-10-3P 711004-11-4P 711004-12-5P
711004-13-6P 711004-14-7P 711004-15-8P
711004-16-9P 711004-17-0P 711004-18-1P
711004-19-2P 711004-20-5P 711004-21-6P
711004-22-7P 711004-23-8P 711004-24-9P
711004-25-0P 711004-26-1P 711004-27-2P
711004-28-3P 711004-29-4P 711004-30-7P
711004-31-8P 711004-32-9P 711004-33-0P
711004-34-1P 711004-35-2P 711004-36-3P
711004-37-4P 711004-38-5P 711004-39-6P
711004-40-9P 711004-41-0P 711004-42-1P
711004-43-2P 711004-44-3P 711004-45-4P
711004-46-5P 711004-47-6P 711004-48-7P
711004-49-8P 711004-50-1P 711004-51-2P
711004-52-3P 711004-53-4P 711004-54-5P
711004-55-6P 711004-56-7P 711004-57-8P
711004-58-9P 711004-59-0P 711004-60-3P
711004-61-4P 711004-62-5P 711004-63-6P
711004-64-7P 711004-65-8P 711004-66-9P
711004-67-0P 711004-68-1P 711004-69-2P
711004-70-5P 711004-71-6P 711004-72-7P
711004-73-8P 711004-74-9P 711004-75-0P
711004-76-1P 711004-77-2P 711004-78-3P
711004-79-4P 711004-80-7P 711004-81-8P
711004-82-9P 711004-83-0P 711004-84-1P
711004-85-2P 711004-86-3P 711004-87-4P
711004-88-5P 711004-89-6P 711004-90-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 711004-91-0P 711004-92-1P 711004-93-2P
711004-94-3P 711004-95-4P 711004-96-5P
711004-97-6P 711004-99-8P 711005-00-4P
711005-01-5P 711005-02-6P 711005-03-7P
711005-04-8P 711005-05-9P 711005-06-0P
711005-07-1P 711005-08-2P 711005-09-3P
711005-10-6P 711005-11-7P 711005-12-8P
711005-13-9P 711005-14-0P 711005-15-1P
711005-16-2P 711005-17-3P 711005-18-4P
711005-19-5P 711005-20-8P 711005-21-9P
711005-22-0P 711005-23-1P 711005-24-2P
711005-25-3P 711005-26-4P 711005-27-5P
711005-28-6P 711005-29-7P 711005-30-0P
711005-31-1P 711005-32-2P 711005-33-3P
711005-34-4P 711005-35-5P 711005-36-6P
711005-37-7P 711005-38-8P 711005-39-9P
711005-40-2P 711005-41-3P 711005-42-4P
711005-43-5P 711005-44-6P 711005-45-7P
711005-46-8P 711005-47-9P 711005-48-0P
711005-49-1P 711005-50-4P 711005-51-5P

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

711005-52-6P 711005-53-7P 711005-54-8P
711005-55-9P 711005-56-0P 711005-57-1P
711005-58-2P 711005-59-3P 711005-60-6P
711005-61-7P 711005-62-8P 711005-63-9P
711005-64-0P 711005-65-1P 711005-66-2P
711005-67-3P 711005-68-4P 711005-69-5P
711005-70-8P 711005-71-9P 711005-72-0P
711005-73-1P 711005-74-2P 711005-75-3P
711005-76-4P 711005-77-5P 711005-78-6P
711005-79-7P 711005-80-0P 711005-81-1P
711005-82-2P 711005-83-3P 711005-84-4P
711005-85-5P 711005-86-6P 711005-87-7P
711005-88-8P 711005-89-9P 711005-90-2P
711005-91-3P 711005-92-4P 711005-93-5P
711005-94-6P 711005-95-7P 711005-96-8P
711005-97-9P 711005-98-0P 711005-99-1P
711006-00-7P 711006-01-8P 711006-02-9P
711006-03-0P 711006-04-1P 711006-05-2P
711006-06-3P 711006-07-4P 711006-08-5P
711006-09-6P 711006-10-9P 711006-11-0P
711006-12-1P 711006-13-2P 711006-14-3P
711006-15-4P 711006-16-5P 711006-17-6P
711006-18-7P 711006-19-8P 711006-20-1P
711006-21-2P 711006-22-3P 711006-23-4P
711006-24-5P 711006-25-6P 711006-26-7P
711006-27-8P 711006-28-9P 711006-29-0P
711006-30-3P 711006-31-4P 711006-32-5P
711006-33-6P 711006-34-7P 711006-35-8P
711006-36-9P 711006-37-0P 711006-38-1P
711006-39-2P 711006-40-5P 711006-41-6P
711006-42-7P 711006-43-8P 711006-44-9P
711006-45-0P 711006-46-1P 711006-47-2P
711006-48-3P 711006-49-4P 711006-50-7P
711006-51-8P 711006-52-9P 711006-53-0P
711006-54-1P 711006-55-2P 711006-56-3P
711006-58-5P 711006-59-6P 711006-60-9P
711006-61-0P 711006-62-1P 711006-63-2P
711006-64-3P 711006-65-4P 711006-66-5P
711006-67-6P 711006-68-7P 713138-04-6P
713138-05-7P 713138-06-8P 713138-07-9P
713138-08-0P 713138-09-1P 713138-10-4P
713138-11-5P 713138-12-6P 713138-13-7P
713138-14-8P 713138-15-9P 713138-16-0P
713138-17-1P 713138-18-2P 713138-19-3P
713138-20-6P 713138-21-7P 713138-22-8P
713138-23-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 711002-73-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)

IT 710978-26-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)

RN 710978-26-0 ZCAPLUS
CN 2-Pyrimidinamine, N-(3S)-[1,1'-bipiperidin]-3-yl-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 11:31:18 ON 01 SEP 2009)

     FILE 'ZCAPLUS' ENTERED AT 11:32:20 ON 01 SEP 2009
L1            1 US20070167459 /PN

     FILE 'REGISTRY' ENTERED AT 11:32:34 ON 01 SEP 2009

     FILE 'ZCAPLUS' ENTERED AT 11:32:34 ON 01 SEP 2009
L2               TRA L1 1- RN :     1829 TERMS

     FILE 'REGISTRY' ENTERED AT 11:32:35 ON 01 SEP 2009
L3           1829 SEA L2
L4           1375 L3 AND NC6/ES AND NCNC3/ES
L5           1265 L4 AND (>=2 NC6/ES OR (NC3 OR NC4 OR NC5)/ES)
L6                STR
L7          10275 (NC6 AND NCNC3)/ES
L8           1375 L7 AND L3
L9             50 L6 SAM SUB=L8
L10          1367 L6 FULL SUB=L8
                  SAV TEM J758CGRCE/A L10
L11          1367 L10 AND L3

     FILE 'ZCAPLUS' ENTERED AT 13:13:32 ON 01 SEP 2009
L12           2 L11

=>
```